Enliven Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELVN research report →
Companywww.enliventherapeutics.com
Enliven Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene.
- CEO
- Richard A. Fair
- IPO
- 2020
- Employees
- 62
- HQ
- Boulder, CO, US
Price Chart
Valuation
- Market Cap
- $2.56B
- P/E
- -26.51
- P/S
- 0.00
- P/B
- 5.78
- EV/EBITDA
- -21.76
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -21.04%
- ROIC
- -25.52%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-103,694,000 · -16.48%
- EPS
- $-1.83 · 3.17%
- Op Income
- $-119,658,000
- FCF YoY
- 3.79%
Performance & Tape
- 52W High
- $48.53
- 52W Low
- $14.79
- 50D MA
- $39.25
- 200D MA
- $26.10
- Beta
- 0.45
- Avg Volume
- 1.10M
Get TickerSpark's AI analysis on ELVN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 26 | Collins Helen Louise | other | 5,000 |
| Apr 17, 26 | Collins Helen Louise | other | 5,000 |
| Apr 17, 26 | Collins Helen Louise | sell | 140 |
| Apr 17, 26 | Collins Helen Louise | sell | 2,419 |
| Apr 17, 26 | Collins Helen Louise | sell | 2,441 |
| Mar 25, 26 | Collins Helen Louise | other | 40,000 |
| Mar 25, 26 | Collins Helen Louise | other | 40,000 |
| Mar 25, 26 | Collins Helen Louise | sell | 40,000 |
| Mar 17, 26 | Collins Helen Louise | other | 5,000 |
| Mar 17, 26 | Collins Helen Louise | other | 5,000 |
Our ELVN Coverage
We haven't published any research on ELVN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ELVN Report →